UNC13A: A Potential Drug Target and Biomarker (G23025)

Target Name: UNC13A

NCBI ID: G23025

UNC13A: A Potential Drug Target and Biomarker

Introduction

Unc13A, also known as unc-13 homolog A, is a non-coding RNA molecule that has been identified in various organisms, including humans. It plays a crucial role in the regulation of gene expression and has been associated with various diseases, including cancer . In this article, we will explore the potential implications of UNC13A as a drug target and biomarker.

Potential Drug Target

UNC13A has been shown to play a role in the regulation of cell proliferation and has been associated with the development of various types of cancer. Its role in cell proliferation is primarily manifested through its ability to regulate the activity of the cell cycle regulator, p21 ( CDK4).

p21 is a critical regulator of the cell cycle that plays a role in preventing the cell from entering into an uncontrolled state of growth, which is a hallmark feature of cancer. UNC13A has been shown to physically interact with p21 and regulate its activity. This interaction between UNC13A and p21 has implications for the development of cancer.

Studies have shown that UNC13A has been overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Overexpression of UNC13A has been associated with the development of cancer-promoting effects, such as increased cell proliferation and the formation of cancer-associated extracellular structures (ECS).

In addition to its role in cancer development, UNC13A has also been shown to play a role in the regulation of cell survival. Studies have shown that UNC13A can interact with the protein Bcl-2 and enhance its survival-promoting effects. This interaction between UNC13A and Bcl-2 has implications for the development of cancer-resistant cells.

Potential Biomarkers

UNC13A has also been identified as a potential biomarker for the diagnosis and monitoring of various types of cancer. Its role in cancer diagnosis and monitoring is primarily manifested through its expression in various types of cancer.

Studies have shown that UNC13A is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This overexpression is associated with the development of cancer-promoting effects and the formation of cancer-associated ECS.

In addition to its role in cancer diagnosis and monitoring, UNC13A has also been shown to play a role in the regulation of cellular processes that are important for cancer progression. Studies have shown that UNC13A can interact with the protein p53 and enhance its tumor suppressor effects . This interaction between UNC13A and p53 has implications for the regulation of cellular processes that are important for cancer progression.

Conclusion

UNC13A has been shown to play a role in the regulation of cell proliferation and cell survival, and its role in cancer development and progression is potentially a drug target and biomarker. Further research is needed to fully understand the role of UNC13A in cancer and to develop Effective treatments based on its potential as a drug target and biomarker.

Protein Name: Unc-13 Homolog A

Functions: Plays a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway. Involved in neurotransmitter release by acting in synaptic vesicle priming prior to vesicle fusion and participates in the activity-dependent refilling of readily releasable vesicle pool (RRP). Essential for synaptic vesicle maturation in most excitatory/glutamatergic but not inhibitory/GABA-mediated synapses. Facilitates neuronal dense core vesicles fusion as well as controls the location and efficiency of their synaptic release (By similarity). Also involved in secretory granule priming in insulin secretion. Plays a role in dendrite formation by melanocytes (PubMed:23999003)

More Common Targets